Evidence map›Paper›PMID 30071276›Full record

ReviewBiochimica et biophysica acta. Molecular basis of disease2019

Animal models for cystic fibrosis liver disease (CFLD).

Romina Fiorotto, Mariangela Amenduni, Valeria Mariotti, Massimiliano Cadamuro, Luca Fabris, Carlo Spirli, Mario Strazzabosco

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta. Molecular basis of disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Romina FiorottoDigestive Disease Section, Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA.
Mariangela AmenduniDigestive Disease Section, Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA.
Valeria MariottiDepartment of Molecular Medicine, University of Padova School of Medicine, Padova, Italy.
Massimiliano CadamuroDepartment of Molecular Medicine, University of Padova School of Medicine, Padova, Italy.
Luca FabrisDepartment of Molecular Medicine, University of Padova School of Medicine, Padova, Italy.
Carlo SpirliDigestive Disease Section, Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA. Electronic address: carlo.spirli@yale.edu.
Mario StrazzaboscoDigestive Disease Section, Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA.
University of Padua · ITYale Cancer Center · USYale University · US

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Liver disease in CF: CFTR controls innate immunity in biliary epitheliumR01DK096096 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2013 to 2022
$4.6M
Cross talk between epithelial, inflammatory and mesenchymal cells in the development of portal fibrosisR01DK101528 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2015 to 2023
$3.5M
Epithelial Angiogenic Signaling in Polycystic Diseases of the LiverR01DK079005 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2008 to 2017
$3.5M
NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK079005NIDDK NIH HHS R01 DK096096NIDDK NIH HHS R01 DK101528
6 · The paper itself

Abstract

Liver disease is a severe complication in patients with Cystic Fibrosis (CF), a genetic disease caused by mutations in the gene encoding for cystic fibrosis transmembrane conductance regulator (CFTR) channel. The sequence of events leading to CFLD is still unclear and has limited the development of more specific treatments other than the bile acid UDCA. However, in the last twenty years, several gaps have been filled, which have mainly been possible due to the availability of different animal models that mimic CF. CF mice, although they lack a spontaneous liver manifestation, have been essential to better understand the multiple functions of CFTR expression on the apical membrane of cholangiocytes, from chloride channel to regulator of epithelial innate immunity. Additionally, we have learned that the gut microbiota might be a pathogenetic factor for the development of liver disease. The recent creation of novel CF animal models (i.e. pig and ferret) that better reproduce the human disease, will allow for comparative studies with species that spontaneously develop the liver disease and will hopefully lead to novel therapeutic treatments. In this review, we have compared and summarized the main features of the current available CF animal models and their applicability for the study of the liver phenotype.

Indexed as

Disease Models, AnimalAnimalsCystic FibrosisGastrointestinal MicrobiomeGene EditingGenetic TherapyHumansImmunity, InnateLiver DiseasesBiliary secretionCFTRCholangiocytesInflammationMicrobiota

Identifiers

PMID30071276
PMCPMC6474816
OpenAlexW2886441987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.